HK1041714A1 - A-beta-peptide screening assay - Google Patents

A-beta-peptide screening assay

Info

Publication number
HK1041714A1
HK1041714A1 HK02103437A HK02103437A HK1041714A1 HK 1041714 A1 HK1041714 A1 HK 1041714A1 HK 02103437 A HK02103437 A HK 02103437A HK 02103437 A HK02103437 A HK 02103437A HK 1041714 A1 HK1041714 A1 HK 1041714A1
Authority
HK
Hong Kong
Prior art keywords
gamma
secretase
beta
screening assay
activity
Prior art date
Application number
HK02103437A
Other languages
English (en)
Inventor
Gisela Peraus
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1041714A1 publication Critical patent/HK1041714A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0335—Genetically modified worms
    • A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/703—Worms, e.g. Caenorhabdities elegans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK02103437A 1998-12-07 2002-05-07 A-beta-peptide screening assay HK1041714A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856261A DE19856261C1 (de) 1998-12-07 1998-12-07 Aß-Peptid Screening Assay
PCT/EP1999/009234 WO2000034511A2 (de) 1998-12-07 1999-11-27 Peptid screening test zum nachweis von ass

Publications (1)

Publication Number Publication Date
HK1041714A1 true HK1041714A1 (en) 2002-07-19

Family

ID=7890159

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103437A HK1041714A1 (en) 1998-12-07 2002-05-07 A-beta-peptide screening assay

Country Status (13)

Country Link
US (1) US7109027B2 (ja)
EP (1) EP1137810B1 (ja)
JP (1) JP4594529B2 (ja)
KR (1) KR100814265B1 (ja)
CN (1) CN1261589C (ja)
AT (1) ATE394505T1 (ja)
AU (1) AU766751B2 (ja)
BR (1) BR9915982A (ja)
CA (1) CA2354154C (ja)
DE (2) DE19856261C1 (ja)
HK (1) HK1041714A1 (ja)
WO (1) WO2000034511A2 (ja)
ZA (1) ZA200104490B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19920514A1 (de) * 1999-05-05 2000-11-16 Boehringer Ingelheim Pharma Methoden zur Auffindung von Proteasen, die spezifisch membrangebundene Substrate spalten
AU2001237412A1 (en) * 2000-02-25 2001-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines
US6713248B2 (en) 2000-04-03 2004-03-30 Bristol-Myers Squibb Company Methods for detection of gamma-secretase activity and identification of inhibitors thereof
EP1268755A1 (en) * 2000-04-05 2003-01-02 Esbatech AG Method to identify polypeptides with protease activity
US7081337B2 (en) 2001-03-30 2006-07-25 Board Of Regents, The University Of Texas System Methods for modulating transcriptional activation using mint proteins
US6649346B2 (en) * 2001-03-30 2003-11-18 Board Of Regents, The University Of Texas Methods of identifying agents that affect cleavage of amyloid-β precursor protein
WO2003011036A1 (en) * 2001-07-27 2003-02-13 Internet Agencies Pty Ltd An improved food product
GB0202276D0 (en) * 2002-01-31 2002-03-20 Eisai London Res Lab Ltd Assays
EP1578356A4 (en) * 2002-02-27 2007-08-15 Merck & Co Inc ASSAYS FOR CONTROLLING MOLECULAR MATURATION OF AN AMYLOID PRECURSOR PROTEIN
US20060068388A1 (en) * 2002-04-18 2006-03-30 Esbatech Ag Method for the identification of modulators of a secretase activity
EP1481987A1 (en) 2003-05-26 2004-12-01 Aventis Pharma Deutschland GmbH Method for screening inhibitors of the gamma-secretase
EP1507147A1 (en) * 2003-08-12 2005-02-16 Erasmus University Medical Center Rotterdam Method for detecting low levels of a fusion protein
US20110104821A1 (en) * 2008-05-08 2011-05-05 Takahiko Tokuda ABeta-OLIGOMER MEASUREMENT METHOD
CN101392027B (zh) * 2008-07-03 2012-04-25 浙江大学 一种治疗阿尔茨海默病的融合蛋白及其制备方法
CN101863962B (zh) * 2010-05-07 2013-02-27 清华大学 抑制beta分泌酶酶切作用的多肽及其应用
CN103450347A (zh) * 2012-05-29 2013-12-18 四川百利药业有限责任公司 一种用于治疗阿尔兹海默症的多肽及基因疫苗
JP6636614B2 (ja) 2015-04-30 2020-01-29 ジャンスー・ヌオ−ベータ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド アルツハイマー病の治療に用いられる薬物および治療標的のスクリーニング方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333269T2 (de) * 1992-01-31 2004-07-29 Abbott Laboratories, Abbott Park Expressionssystem in säugetieren für hcv-proteine
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
WO1994028412A1 (en) * 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
JPH07132033A (ja) * 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
WO1996040885A2 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
CA2183901A1 (en) * 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
AU1684097A (en) * 1996-12-11 1998-07-03 Athena Neurosciences, Inc. Beta-secretase isolated from human 293 cells
DE19849073A1 (de) * 1998-10-24 2000-04-27 Aventis Pharma Gmbh Transgener C. elegans als Modellorganismus für Untersuchungen zur Alzheimer'schen Krankheit

Also Published As

Publication number Publication date
AU766751B2 (en) 2003-10-23
AU1968000A (en) 2000-06-26
CA2354154A1 (en) 2000-06-15
CN1261589C (zh) 2006-06-28
JP2002531141A (ja) 2002-09-24
US20010034884A1 (en) 2001-10-25
DE19856261C1 (de) 2000-03-30
KR100814265B1 (ko) 2008-03-18
EP1137810A2 (de) 2001-10-04
WO2000034511A2 (de) 2000-06-15
DE59914752D1 (de) 2008-06-19
WO2000034511A3 (de) 2000-11-16
CA2354154C (en) 2011-01-04
JP4594529B2 (ja) 2010-12-08
EP1137810B1 (de) 2008-05-07
US7109027B2 (en) 2006-09-19
KR20010080695A (ko) 2001-08-22
ATE394505T1 (de) 2008-05-15
BR9915982A (pt) 2001-09-11
CN1329674A (zh) 2002-01-02
ZA200104490B (en) 2002-06-04

Similar Documents

Publication Publication Date Title
HK1041714A1 (en) A-beta-peptide screening assay
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
ES2058725T3 (es) Aplicacion transdermica de 2-amino-6-n-propilamino-4,5,6,7-tetrahidrobenzotiazol.
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ATE209044T1 (de) Eine stabilisierte phenylalanin-ammonia-lyase
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
AU2002365646A1 (en) Novel proteins with il-6 inhibiting activity
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
CA2379821A1 (en) Mixture for the treatment of waste materials
TR199902564T2 (xx) K�k�rdak oligomer matris proteininin romatoid artrit tedavisinde kullan�m�.
DE69006360T2 (de) L-alpha-glycerophosphoryl-d-myoinositol zur behandlung peripherer neuropathien und cerebropathien.
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
WO2001049871A3 (en) Process for finding a protease inhibitor
ATE291435T1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE452143T1 (de) Verwendung des multifunktionellen transkriptionsfaktors yin-yang-1 und varianten davon zur behandlung von typ-1 diabetes
WO2003087289A3 (en) Methods for the selection of compounds useful for the treatment of huntington’s disease
WO2003090771A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)
ATE223211T1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit
BR9906931A (pt) Triazepinonas, processo para sua preparação e sua aplicação terapêutica

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151127